Edwards CEO Mussallem details U.S. Sapien sales guidance, updates on CoreValve case | Wall Street Beat

MassDevice.com Wall Street Beat

Edwards Lifesciences (NYSE:EW) chairman & CEO Michael Mussallem said the medical device company expects to post U.S. sales of $390 million-$440 million for its flagship Sapien heart valve, adding 200 new sites over the next 2 years to its existing roster of 200 sites.

"The U.S. is off to a good start," Mussallem said yesterday at the J.P. Morgan healthcare conference in San Francisco. "We think this grows for many, many years into the future."

Edwards expects to post sales growth of 13%-16% this year, he said, with earnings-per-share growth of more than 25%. Free cash flow is forecast to reach a new high of $300 million to $340 million, Mussallem said.

Sign up to get our free newsletters delivered straight to your inbox

As for Edwards’ long-running battle with Medtronic‘s (NYSE:MDT) CoreValve subsidiary over patents covering the Sapien transcatheter aortic valve implant, the end could be nigh, Mussallem said.

"The odds are pretty substantial here that we’re getting to the end of this," he said, citing an appeals court decision upholding a $74 million judgment in Edwards’ favor. "My guess is that Medtronic tries to execute some kind of strategy so they’re not shut out of the U.S."

Edwards expects to enjoy patent exclusivity until 2016 or 2017, Mussallem added.

 Mako Surgical’s prelims send shares to a new low
Shares of Mako Surgical (NSDQ:MAKO) are down nearly 4% today, to a 52-week low, after the medical device company reported preliminary 4th-quarter and 2012 sales and procedure volumes for its Rio surgical robot system.

Mako, which is expected to reveal preliminary sales and earnings figures at the J.P. Morgan healthcare conference tomorrow, said it sold 15 Rio systems during the 4th quarter and 45 during 2012, for a total installed base of 156 systems worldwide. More than 2,904 Makoplasty procedures were performed during the quarter, up 20% over the 3rd quarter and 29% over Q4 2011.

Wall Street investors were not reassured, however, sending MAKO shares down 8.9% to $11.33 apiece yesterday and down another 4.2% today as of about 12:45 p.m., to $10.85 per share.
Read more

 Orthofix plunges on prelims
Orthofix (NSDQ:OFIX) said it expects 4th-quarter sales of about $112 million and 2012 sales from continuing operations of roughly $462 million, with Q4 adjusted earnings per share of 78¢-83¢ and full-year adjusted EPS of $3.01-$3.06

But The Street, incited by big hits from what Orthofix called "regulatory and macroeconomic conditions" and "sales force turnover" in its spine regenerative stimulation business, sent OFIX shares down 4.5% today as of about 1:30 p.m., to $36.16 apiece.
Read more

 Endologix stays flat after announcing prelims

Endologix (NSDQ:ELGX) said it expects Q4 sales of about $29.2 million and 2012 revenues of roughly $105.9 million, amounting to 25% and 27% year-over-year growth, respectively.

That’s in-line with its prior sales guidance, prompting The Street to keep share prices flat at $14.73 each as of about 1:30 p.m. today.
Read more

 Greatbatch gains on prelims, guidance
Shares of Greatbatch (NYSE:GB) were up sharply today after the medical device company reported strong preliminary Q4 and 2012 results and issued its guidance for the new year.

Greatbatch said its 2012 sales were up 13.5% to about $645 million, with adjusted EPS of $1.75-$1.85, in-line with its prior outlook. Sales this year are forecast to grow between 2% and 5%, with adjusted EPS growth of 7% to 13%.

The Street seemed to like what it heard, sending GB shares up 3.5% to $24.50 each as of about 1:30 p.m. today.
Read more

 Analysts’ ups and downs

  • Abbott (NYSE:ABT): BMO Capital Markets initiates at “outperform” rating, $36 price target; Deutsche Bank downgrades from "buy" to "hold" rating, lowers price target from $70 to $33; Leerink Swann maintains $30 price target, "market perform" rating.
  • AthenaHealth (NSDQ:ATHN):
  • Piper Jaffray & Co. reiterates “overweight” rating, $100 price target.

  • AtriCure (NSDQ:ATRC): Leerink Swann maintains “outperform” rating, ~$10 price target.
  • Baxter (NYSE:BAX): Deutsche Bank maintains "hold" rating, raises price target to $71.
  • Becton Dickinson & Co. (NYSE:BDX): Deutsche Bank maintains "hold" rating, raises price target to $85; Morgan Stanley raises from "underweight" to "equal-weight" rating, removes $68 price target; Piper Jaffray reiterates "neutral" rating, $74 price target.
  • Bruker Corp. (NSDQ:BRKR): ISI Group upgrades from "neutral" to "buy" rating, maintains $19 price target.
  • C.R. Bard (NYSE:BCR): Deutsche Bank maintains "hold" rating, raises price target to $97.
  • Covidien (NYSE:COV): Citigroup reiterates “buy” rating, maintains $64 price target; Goldman Sachs reiterates "neutral" rating, raises price target from $62 to $63.
  • Cynosure (NSDQ:CYNO): Zacks downgrades from “outperform” to “neutral” rating, $25.40 price target.
  • Danaher (NYSE:DHR): ISI Group upgrades from "neutral" to "buy" rating, maintains $64 price target.
  • (NSDQ:DXCM): Leerink Swann maintains “market perform” rating, ~$14 price target.
  • Edwards Lifesciences (NYSE:EW): Deutsche Bank increase price target from $85 to $90, maintains”hold” rating; JMP Securities initiates with "market perform" rating.
  • Globus Medical (NYSE:GMED): Leerink Swann reiterates "outperform" rating, lowers price target from $19-$20 to $17.
  • HeartWare International (NSDQ:HTWR): Leerink Swann reiterates “outperform” rating, $105 price target.
  • Henry Schein (NSDQ:HSIC): ISI Group upgrades from "underweight" to "neutral" rating, sets $84 price target.
  • Hologic (NSDQ:HOLX): Zacks reiterates “neutral” rating, $21 price target
  • Insulet (NSDQ:PODD): Canaccord Genuity reiterates "buy" rating, raises price target from $24.50 to $29.
  • Intuitive Surgical (NSDQ:ISRG): Zacks upgrades from “neutral” to “outperform” rating, maintains $597 target price; Raymond James reiterates "outperform" rating, $620 price target.
  • Mako Surgical (NSDQ:MAKO): Leerink Swann maintains “market perform” rating, $15 price target.
  • Medtronic (NYSE:MDT): Deutsche Bank boosts price target from $45 to $46, maintains”hold” rating; Mizuho upgrades from "neutral" to "buy" rating, sets $49 price target; Oppenheimer reiterates "outperform" rating, maintains $48 price target.
  • Mindray (NYSE:MR): Oppenheimer raises reiterates “outperform” rating, $39 price target.
  • NuVasive Inc. (NSDQ:NUVA): BMO Capital upgrades to “market perform” rating, raises price target to $17.
  • Palomar Medical (NSDQ:PMTI): Zacks lowers from “neutral” to “underperform” rating, sets $8.70 price target.
  • Smith & Nephew (FTSE:SN, NYSE:SNN): Alphavalue downgrades from "sell" to "reduce" rating, raises target price from £5.956 to £6.572.
  • TranS1 (NSDQ:TSON): Barrington Research initiates coverage with $4 price target, “outperform” rating
  • Volcano (NSDQ:VOLC): Leerink Swann reiterates “outperform” rating, $32 price target.
  • Zeltiq (NSDQ:ZLTQ): Goldman Sachs reiterates "neutral" rating, reduces price target from $5 to $4.60.

RSS From Medical Design & Outsourcing

  • Molex delivers ISO 13485-compliant, medical-grade surgical cables from its class 100,000 clean room facility
    Molex, LLC operates a fully ISO 146441-1:1999 Class 8-certified clean room, satisfying strict particulate contamination levels specified by ISO-compliant requirements. Located in Thailand, the facility has less than 100,000 particulates (≥0.5µm) per cubic foot of air and manufactures a variety of ISO 13485-compliant medical cables and surgical cables used in operating theatres, hospitals, laboratories and […]
  • Swept-Source OCT: Patent license agreement between Massachusetts General Hospital and Heidelberg Engineering
    Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications which relate to swept-source OCT technology and its application in ophthalmology. Spectral domain OCT has become indispensable to eye care professionals worldwide to diagnose and […]
  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]
  • First ‘Ear Wear’ for Active Adults Debuts with MDHearingAid FIT
    If you’ve burned out your ears with earbuds, headphones or decades of other audio abuse but aren’t ready for your grandmother’s hearing aids, not to worry! The new MDHearingAid FIT gets you back in the game with a tiny, FDA-registered, one-size-fits-most solution that doesn’t block your ear canal like old-fashioned in-the-ear hearing aids. The FIT feels […]
  • CardioGenics enters into manufacturing agreement with Ontario-based Plasticap
    CardioGenics Holdings, developer for the In-Vitro-Diagnostics (“IVD”) testing market, announced that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics’ proprietary self-metering cartridges for its QL Care analyzer. The term of the agreement is three years and the purchase price for each cartridge shall be […]
  • MTD Micro Molding releases micro materials menu
    MTD Micro Molding, a long-time leader in micro-injection molding, has released an updated “Materials Menu” of materials that can be successfully micromolded to help guide engineers at medical device companies. Material selection is a crucial step in product manufacturability. The correct material drives tolerance, dimension, strength, usabality, speed-to-market, design, critical features, and cost. Through MTD’s […]
  • MedTech Chat: Elastic technology for drug delivery
    Dr. Zhen Gu and Dr. Yong Zhu from North Carolina State University are both co-senior authors of a research paper describing their recent work. Dr. Gu, Dr. Zhu and other researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug delivery technology that consists of an […]
  • B. Braun’s OEM Division offers large bore normally closed low-pressure check valves
    Infusion therapy and pain management device manufacturer B. Braun said today it is offering normally closed large-bore low-pressure check valves through its valve-focused contract manufacturing OEM division. The valves, offered by Bethlehem, Pa.-based B. Braun, are designed for the intermittent injection of fluids during medical treatment and open automatically when pressure is applied. The newly […]

Leave a Reply